REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
08/06/2026
Voltar para busca
Dado oficial do USPTO
CENTER FOR BREAKTHROUGH MEDICINES
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
CENTER FOR BREAKTHROUGH MEDICINES
ST13
US500000088981530Classe
40, 42
Pedido
88981530
Registro
6382057
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
09/06/2026
Tipo de marca
Verbal
Classes Nice
40, 42
Data de depósito
12/12/2019
Data de registro
08/06/2021
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
08/06/2021
Última transação
09/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
16/03/2021
Primeiro uso no comércio
16/03/2021
Código do desenho
4
Tipo de titular
16
Localização do titular
KING OF PRUSSIA, PA, US
Examinador
STEEL, ALYSSA PALADINO
Unidade examinadora
N60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC
MORNING LIGHT IP, LLC
Representantes
Joshua M. Gerben, Esq. GERBEN LAW FIRM, PLLC
Classificação técnica
Classes Nice
Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 40
Manufacturing services for others in the fields of gene therapymodified gene therapycell therapytissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banksplasmidsadenovirusadeno-associated virus (AAV)bacteriophagelentivirusretroviruses and other viruses found in humans and animals; manufacturing process consulting
Classe 42
Research and development services in the fields of gene therapymodified gene therapycell therapytissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapymodified gene therapycell therapytissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapymodified gene therapycell therapytissue engineering and biopharmaceuticals; scientific research and technical research servicesproduction of cell lines for others using lentivirus technology; scientific research and technical research services relating to producingassaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producingassayingpurifying adenovirusadeno-associated virus (AAV)bacteriophagelentivirusretroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for otherscGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management servicesquality evaluation and analysisquality assurancequality controlin the fields of gene therapymodified gene therapycell therapytissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
19/10/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
08/06/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
06/05/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/05/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
03/05/2021
DPCC
DIVISIONAL PROCESSING COMPLETE
03/05/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
26/04/2021
IUAF
USE AMENDMENT FILED
05/04/2021
DRRR
DIVISIONAL REQUEST RECEIVED
05/04/2021
EISU
TEAS STATEMENT OF USE RECEIVED
05/04/2021
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
05/04/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/03/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/01/2021
PUBO
PUBLISHED FOR OPPOSITION
12/01/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
23/12/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/12/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/12/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/12/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/12/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
30/06/2020
GNRT
NON-FINAL ACTION E-MAILED
30/06/2020
CNRT
NON-FINAL ACTION WRITTEN
30/06/2020
DOCK
ASSIGNED TO EXAMINER
26/06/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
26/06/2020
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
12/05/2020
ALIE
ASSIGNED TO LIE
28/04/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
22/04/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/04/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/04/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/04/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
16/03/2020
GNRT
NON-FINAL ACTION E-MAILED
16/03/2020
CNRT
NON-FINAL ACTION WRITTEN
16/03/2020
DOCK
ASSIGNED TO EXAMINER
12/03/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
16/12/2019
NWAP
NEW APPLICATION ENTERED
16/12/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CENTER FOR BREAKTHROUGH MEDICINES ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.